Brokerage : Yuanta Securities
Analyst : Hyunsoo Ha
Investment Rating : BUY (Coverage Resumed)
Target Price : KRW 150,000 (Upward)
Core Momentum : Value realization driven by confirmed clinical safety of pPBD, potential of LCB39 to address toxicity hurdles, and LCB84’s differentiation in overcoming Topo1i resistance
📊 1. [Valuation & Key Financial Metrics]
- Investment Rating & Target Price: BUY (Coverage Resumed), Target Price KRW 150,000 (Raised from previous KRW 140,000), Upside Potential 37% (Based on closing price of KRW 109,300 on 2025-05-21)
- Pipeline Valuation Scope: Target price incorporates valuations of LCB84 and LCB14 (LCB71 value to be integrated post-verification of solid tumor efficacy and safety in R-CHOP combination)
- Financial Forecasts & Historicals (K-IFRS Consolidated):
- 2023A: Revenue KRW 34 Billion, Operating Profit KRW -81 Billion, Controlling Net Profit KRW -74 Billion, PER -14.1x, PBR 7.5x, EV/EBITDA -12.3x, ROE -40.1%
- 2024A: Revenue KRW 126 Billion, Operating Profit KRW -21 Billion, Controlling Net Profit KRW 8 Billion, PER 362.6x, PBR 4.8x, EV/EBITDA -147.3x, ROE 2.0%
- 2025F: Revenue KRW 218 Billion, Operating Profit KRW 17 Billion, Controlling Net Profit KRW 29 Billion, PER 139.2x, PBR 6.1x, EV/EBITDA 166.3x, ROE 4.6%
- 2026F: Revenue KRW 309 Billion, Operating Profit KRW 53 Billion, Controlling Net Profit KRW 60 Billion, PER 66.4x, PBR 5.6x, EV/EBITDA 61.4x, ROE 8.9%
- Trading & Stock Metrics: Market Cap KRW 4,001.5 Billion, Total Outstanding Shares 36,610,338 shares, 60-Day Avg Daily Trading Value KRW 32.9 Billion, 60-Day Avg Daily Volume 313,079 shares, 52-Week High/Low KRW 140,000 / KRW 61,900, Foreign Ownership 11.03%, Dividend Yield 0.00%, Major Shareholders Pan Orion Corp. Limited & 8 affiliated parties
🚀 2. [Market Opportunities & Business Outlook]
- Payload Platform Competitiveness & Safety Profiles:
- Utilizing PBD Prodrug (pPBD) to address key safety limitations and off-target/off-site toxicity associated with conventional ADCs; demonstrated superior safety profile in ROR1 ADC (CS5001/LCB71).
- CS5001 Phase 1b expansion into solid tumors aims to further enhance pPBD platform valuation upon efficacy confirmation.
- LCB39 (STING agonist) is designed with metabolites presumed to act as primary active agents, presenting potential to overcome side-effect limitations seen in conventional STING agonists.
- Market Opportunities for TROP2 ADC (LCB84):
- Dato-DXd’s Phase 3 AVANZAR trial results in 1L NSCLC scheduled for release in 2H25, accelerating overall TROP2 ADC development momentum.
- Unlike most Trop-2 ADCs utilizing Topo1 inhibitors, LCB84 employs an MMAE payload, establishing distinct mechanistic differentiation.
- Distinct payload mechanism positions LCB84 favorably as a second-line or later (2L+) therapeutic option for patients refractory to prior Topo1i ADCs.
📝 Editor’s Comment (Perspective)
The covering analyst views LigaChem Biosciences as a chemistry-driven ADC biotech capable of overcoming fundamental safety and toxicity bottlenecks in the ADC landscape through proprietary prodrug payload engineering. This perspective prioritizes clinical safety validation of pPBD, the potential of novel payload chemistries like LCB39 to overcome toxicity limits, and strategic mechanistic diversification over basic pipeline volume.
To verify whether this investment thesis continues to materialize, primary focus should be directed toward solid tumor clinical data and R-CHOP combination safety readouts for CS5001 (LCB71), alongside clinical progression of LCB84 as a differentiated option in Topo1i-resistant settings following the 2H25 AVANZAR readout. These operational developments can be monitored through upcoming corporate IR presentations, medical congress disclosures, and official regulatory filings.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
